BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P43
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | -4.87% |
| 2024 | -19.36% |
| 2023 | -14.50% |
| 2022 | 21.31% |
| 2021 | 69.81% |
| 2020 | 14.85% |
| 2019 | 26.13% |
| 2018 | 26.77% |
| 2017 | 9.76% |
| 2016 | -16.15% |